Modern

• The U.S. Army Rangers suffered 18 deaths during the "Black Hawk Down" incident in Mogadishu on October 3–4, 1993. • Images of soldiers' bodies being dragged through the streets led the Clinton administration to withdraw forces within months. • This event created a long-term reluctance within the U.S. government to intervene in international humanitarian crises.

• A U.S. Air Force colonel, known by the call sign "Bravo," recounted his survival and rescue after being shot down over Iran during ongoing fighting in the Strait of Hormuz. • The pilot described his emergency ejection and subsequent extraction from behind enemy lines as a "modern-day miracle." • This account highlights the high operational risks for U.S. military personnel currently deployed in the Middle East conflict.

• India is seeking to expand its influence in West Asia by positioning itself as a credible security convenor through its strategic ties and BRICS membership. • The proposed role focuses on non-military mandates such as crisis communication, preventive diplomacy, humanitarian coordination, and maritime security. • This shift would allow New Delhi to shape regional stability without relying on formal military treaties or traditional defense arrangements.

Georgia O’Keeffe inspires the latest Calvin Klein while Michael Kors feels indebted to Alexander CalderCalvin Klein has taken a highbrow turn in the two years since Veronica Leoni took charge. The Italian designer, a philosophy graduate who was schooled in the chic design studios of Jil Sander and Celine, has shifted away from jeans, boxer shorts and logos, stripping the brand to its minimalist bones: slip dresses and simple coats, slim skirts and crisp T-shirts.Leoni called this the “discipline of removal”. Her muse this season was Georgia O’Keeffe, an artist who the brand’s namesake founder admired. Klein bought O’Keeffe’s painting Summer Days in 1983 for $1m, subsequently donating it to the Whitney Museum. A checked pattern taken from O’Keeffe’s distinctive capsule wardrobe of utilitarian chic appeared on this catwalk as a wrap coat, hardware-free with a fabric belt and no buttons. Continue reading...

• India is currently navigating a strategic rivalry between the United States and China as both superpowers compete for global dominance. • The conflict centers on a struggle for technological leadership, economic control, and the rewriting of national security rules. • New Delhi risks losing its strategic autonomy, or its ability to make independent foreign policy decisions, if it is forced to choose a side in a bipolar world order.

• Modern Healthcare is tracking the latest news on mergers, acquisitions, and joint partnerships in the healthcare industry. • The publication provides live updates on deals as they happen, giving readers insight into the changing healthcare landscape. • This coverage helps healthcare professionals and investors stay informed about potential opportunities and challenges in the market.

The former National Socialist Network is challenging ban in high court, arguing law breaches implied freedom of political communicationFollow our Australia news live blog for latest updatesGet our new political email, free app or daily news podcastThe White Australia party is a “modern manifestation” of Adolf Hitler’s Nazi movement and would motivate hate crimes against sections of the country, the high court has heard.The White Australia party, formerly known as the National Socialist Network (NSN), was designated as an illegal hate group in May after the Australian Security and Intelligence Organisation (Asio) passed on its recommendation to the home affairs minister, Tony Burke. Continue reading...

• EU foreign ministers met in Wicklow, Ireland, on September 1–2 for an informal “Gymnich” session to address Ukraine's 2027 funding gap. • Sweden, the Netherlands, Spain, and Poland proposed reviving a plan to convert approximately $200 billion in frozen Russian central bank assets, primarily held at Euroclear, into a “reparations loan” for Kyiv. • The initiative aims to secure long-term financial support for Ukraine, though the plan was previously blocked by Belgium in December.

Exclusive: Home Office concedes skilled workers abused by sponsors can change employer and complete visa termUK politics live – latest updatesCare workers, chefs and others in danger of losing their migration status under post-Brexit rules if they leave an exploitative employer will be helped by new visa changes, the Home Office says.Officials said if an employee was found to be a victim of modern slavery they would be allowed to work for any employer for the remainder of their visa. Continue reading...

• Moderna and Merck have reported positive results from a large Phase 3 clinical trial of a personalized mRNA-based cancer vaccine designed to treat melanoma. • Unlike traditional treatments, this therapy trains a patient's own immune system to recognize and destroy the specific cancer cells threatening them. • This breakthrough represents a major step forward in precision oncology, moving away from broad attacks on cancer cells toward highly targeted immunotherapy.

• Moderna and Merck are developing personalized cancer vaccines designed to train the immune system to target mutations specific to an individual's tumor. • The treatment represents a potential breakthrough in oncology by shifting toward highly tailored immunotherapy rather than one-size-fits-all approaches. • Clinical trial results for colon cancer are anticipated in 2027, with data for pancreatic cancer trials expected to follow by 2031.

• Moderna and Merck announced that a personalized mRNA cancer vaccine successfully slowed the recurrence and spread of melanoma in a late-stage clinical trial. • The vaccine was administered in combination with Merck's immunotherapy drug, Keytruda, to enhance the body's immune response against the cancer. • This result is significant as it demonstrates the potential for mRNA technology to be adapted for oncology, moving beyond its success in COVID-19 vaccinations.

• Merck and Moderna announced that their cancer vaccine, intismeran, successfully met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 trial. • The study focused on patients with completely resected stage IIB-IV melanoma, marking a significant milestone in testing whether Moderna's mRNA technology can be effectively applied to oncology. • This success is part of a broader strategy to treat cancer earlier in its progression, with Merck currently conducting over 30 registrational studies across various cancer types.

• Moderna and Merck announced that a personalized mRNA cancer vaccine, used alongside the immunotherapy drug Keytruda, successfully reduced the risk of recurrence and spread of melanoma in a late-stage trial. • The positive interim analysis caused Moderna’s shares to surge by as much as 160 per cent on Wednesday. • This development marks a significant milestone in the emerging field of personalized cancer treatment, potentially benefiting thousands of high-risk patients who have undergone tumor removal surgery.

• Merck and Moderna announced that an experimental cancer vaccine-drug combination shows promise in preventing the recurrence of melanoma in high-risk patients. • While full trial data has not yet been published, previous research presented in June at the American Society of Clinical Oncology meeting indicated the treatment halved the risk of recurrence over five years for 157 patients. • This development is significant as it suggests a potential breakthrough in long-term cancer survival and the prevention of relapse for high-risk individuals.

• Merck and Moderna announced that their personalized mRNA vaccine successfully met its goals in a late-stage trial by preventing skin cancer from returning in high-risk melanoma patients. • While the results have been met with enthusiasm from observers, the companies have not yet released the full data from the ongoing study. • This development marks a significant step in applying mRNA technology to oncology, following Moderna's recent FDA approval for an mRNA flu shot.

• Merck and Moderna announced on Wednesday that their experimental cancer vaccine significantly reduced the return and spread of disease in a trial of over 1,000 melanoma patients. • The study focused on patients with high-risk localized tumors that had been surgically removed, aiming to prevent recurrence. • This breakthrough is significant as it could usher in a new wave of personalized cancer vaccines, with Moderna estimating thousands of patients could benefit shortly after approval.

• Merck and Moderna announced that their Phase 3 INTerpath-001 trial met primary endpoints for recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected stage IIB-IV melanoma. • The study found that combining KEYTRUDA with intismeran autogene—an mRNA-based individualized neoantigen therapy tailored to a patient's specific tumor mutations—provided statistically significant improvements over using KEYTRUDA alone. • This marks the first and only combination regimen to demonstrate such clinically meaningful improvements in the adjuvant melanoma setting.

• Global oil markets are shifting their expectations to account for a potentially prolonged crisis in the Strait of Hormuz, rather than a brief geopolitical shock. • Analysts are evaluating whether persistent disruptions in this critical shipping lane could sustain elevated oil prices through 2027. • This shift matters because the Strait of Hormuz is a primary artery for global energy supplies, and long-term instability threatens global economic stability and inflation.

• The FDA has approved Moderna's new mRNA-based flu vaccine, named mFlusiva, which is specifically intended for adults aged 50 and older. • This approval marks a shift toward using mRNA technology for seasonal influenza, moving away from traditional egg-based vaccine production methods. • The development is significant as it aims to provide more precise and potentially more effective protection against evolving flu strains.

• The FDA approved mFlusiva, the first mRNA-based flu vaccine developed by Moderna, on Wednesday. • The vaccine is approved for adults aged 50 to 65 and those 65 and older, with late-stage trials showing it is approximately 27% more effective than standard flu shots. • This approval is significant as it applies the same messenger RNA platform used in Pfizer and Moderna's COVID-19 vaccines to seasonal influenza.

• Moderna has launched a first-in-human Phase 1 clinical trial (NCT07737717) for mRNA-1469, an investigational vaccine targeting the Bundibugyo ebolavirus (BDBV). • The study is being conducted across three sites in Canada and aims to enroll approximately 80 healthy adult participants to evaluate safety, tolerability, and immunogenicity. • This development is critical because while vaccines exist for Zaire ebolavirus, there are currently no approved vaccines to protect against BDBV, which has caused outbreaks in the Democratic Republic of the Congo.

• Nutanix is introducing a unified operational model that integrates virtual machines, Kubernetes, and bare metal to reduce infrastructure duplication and support edge AI. • The transition toward consolidating platform teams varies by organization, as timelines are heavily influenced by internal politics, licensing, and existing skill sets. • The shift is driven by the rise of AI inference at the edge, which is repositioning bare metal as a primary deployment target rather than a niche requirement.

• The U.S. FDA has approved Moderna's first mRNA-based influenza vaccine specifically for adults aged 50 and older. • This decision follows a reversal of a previous refusal and leverages mRNA technology that was rapidly accelerated and proven safe during the COVID-19 pandemic. • The approval is significant as it expands the use of mRNA technology to combat seasonal diseases, while Health Canada is currently considering its own approval of the shot.

• Health Canada has approved a Phase I clinical trial for Moderna’s mRNA vaccine candidate targeting the Bundibugyo virus, a species of Ebola. • Canada becomes the second nation to authorize this trial, following a similar approval in the United Kingdom. • The move comes after the World Health Organization declared the current outbreak a public health emergency of international concern on May 17.

• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform. • This approval is critical as it demonstrates the potential for mRNA technology to address broader public health challenges beyond COVID-19.

The mFlusiva vaccine for older people is first made with mRNA platform key to ending coronavirus pandemicThe Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, Moderna, the manufacturer, said.The shot, named mFlusiva, is intended for adults aged 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late on Wednesday that it expected some of its new version to be available soon at select retailers. Continue reading...

• The FDA has approved Moderna’s mFlusiva, marking the first time a licensed influenza vaccine has been developed using messenger RNA (mRNA) technology. • This approval represents a significant milestone for mRNA, a platform that gained global prominence during the COVID-19 pandemic but has faced scrutiny from vaccine skeptics. • The shift to mRNA for flu shots is critical because the technology allows for faster production and potentially better matching to evolving seasonal virus strains.